|
Solid Neoplasm
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
This multicenter, open-label, phase Ib study investigated the safety and efficacy of binimetinib (MEK inhibitor) in combination with buparlisib (phosphatidylinositol 3-kinase [PI3K] inhibitor) in patients with advanced solid tumors with <i>RAS/RAF</i> alterations.
|
31395751 |
2020 |
|
Solid Neoplasm
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors.
|
31619463 |
2020 |
|
Solid Neoplasm
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
Previous case reports have shown the promising antitumor activity of everolimus in solid tumors containing molecular aberrations in PI3K/ATK/mTOR pathway, however, whether it is effective in patients with breast cancer remains unknown.
|
31385461 |
2019 |
|
Solid Neoplasm
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
Buparlisib (BKM-120) is an orally active pan-PI3K inhibitor evaluated in different solid tumors as monotherapy or in combination.
|
31159599 |
2019 |
|
Solid Neoplasm
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
This report describes the landscape of PI3K alterations in solid tumors as well as co-alterations serving as potential resistance/attenuation mechanisms.
|
30582752 |
2019 |
|
Solid Neoplasm
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
BYL719 (BYL) is a PI3Kα-selective small molecule inhibitor and a prospective drug for advanced solid tumors.
|
31095940 |
2019 |
|
Solid Neoplasm
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Successive cohorts of patients with advanced solid tumors with PI3K pathway activation received increasing CLR457 doses according to a Bayesian escalation model based on the rate of dose limiting toxicity (DLT) in the first 28-day cycle.
|
30073466 |
2019 |
|
Solid Neoplasm
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Strategies to ameliorate drug-related toxicities, use of rational combinations with PI3K antagonists, development of mutant-selective PI3K inhibitors, and better patient selection should improve the success of these targeted agents against solid tumors.
|
30867161 |
2019 |
|
Solid Neoplasm
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II).
|
31392595 |
2019 |
|
Solid Neoplasm
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
The catalytic subunit p110δ of phosphoinositide 3-kinase (PI3K) encoded by PIK3CD has been implicated in some human solid tumors.
|
30618098 |
2019 |
|
Solid Neoplasm
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
The PI3Kα inhibitor alpelisib achieved a 58.2% disease control rate in <i>PIK3CA</i>-altered solid tumors.
|
29453241 |
2018 |
|
Solid Neoplasm
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Until now, PI3K targeting in solid tumors has focused on inhibiting PI3Kα-mediated and PI3Kβ-mediated cancer cell-intrinsic PI3K activity.
|
30300952 |
2018 |
|
Solid Neoplasm
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
These preliminary data suggest that taselisib may be effective in patients with PIK3CA-mutated solid tumors or HR-positive advanced breast cancer.
|
29500843 |
2018 |
|
Solid Neoplasm
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
In the dose-expansion phase, patients with PIK3CA-altered solid tumors and PIK3CA-wild-type, estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast cancer received alpelisib 400 mg once daily.
|
29401002 |
2018 |
|
Solid Neoplasm
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors.
|
29051322 |
2018 |
|
Solid Neoplasm
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
A phase I trial of pilaralisib, an oral pan-class I phosphoinositide 3-kinase (PI3K) inhibitor, established the maximum tolerated dose (MTD) of the capsule formulation in patients with advanced solid tumors as 600 mg once daily.
|
29593099 |
2018 |
|
Solid Neoplasm
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Intense efforts have been made to elucidate resistance mechanisms and identify rational drug combinations with PI3K inhibitors in solid tumors.
|
30042442 |
2018 |
|
Solid Neoplasm
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).
|
29660598 |
2018 |
|
Solid Neoplasm
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
The human epidermal growth factor receptor 2 (HER2)/phosphoinositide 3-kinase (PI3K) axis, an important oncogenic pathway, has been targeted for therapy in several solid tumors.
|
30289966 |
2018 |
|
Solid Neoplasm
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
We administered repeated infusions of lipid nanoparticles coated with the tumor-targeting peptide iRGD and loaded with a combination of a PI3K inhibitor to inhibit immune-suppressive tumor cells and an α-GalCer agonist of therapeutic T cells to synergistically sway the tumor microenvironment of solid tumors from suppressive to stimulatory.
|
29760047 |
2018 |
|
Solid Neoplasm
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
Background Voxtalisib, a PI3K/mTOR inhibitor, has shown antitumor activity in capsule formulation in patients with solid tumors.
|
28417284 |
2018 |
|
Solid Neoplasm
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
This phase I, four-arm, open-label study (NCT01347866) evaluated the PI3K/mTOR inhibitors PF-04691502 (arms A, B) and gedatolisib (PF-05212384; arms C, D) in combination with the MEK inhibitor PD-0325901 (arm A, D) or irinotecan (arm B, C) in patients with advanced solid tumors.
|
29067643 |
2017 |
|
Solid Neoplasm
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Numerous PI3K inhibitors including pan-PI3K, isoform-selective and dual PI3K/mammalian target of rapamycin (mTOR) inhibitors have exhibited favorable preclinical results and entered clinical trials in a range of hematologic malignancies and solid tumors.
|
28592260 |
2017 |
|
Solid Neoplasm
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Phase Ia/Ib study of the pan-class I PI3K inhibitor pictilisib (GDC-0941) administered as a single agent in Japanese patients with solid tumors and in combination in Japanese patients with non-squamous non-small cell lung cancer.
|
27565810 |
2017 |
|
Solid Neoplasm
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Purpose We previously reported the phase I dose escalation study of buparlisib, a pan-class 1A PI3K inhibitor, combined with platinum/taxane-based chemotherapy in patients with advanced solid tumors.
|
28281183 |
2017 |